The role of imaging in the management of progressive glioblastoma: A systematic review and evidence-based clinical practice guideline

Timothy Charles Ryken, Nafi Aygun, Johnathan Morris, Marin Schweizer, Rajeshwari Nair, Cassandra Spracklen, Steven N. Kalkanis, Jeffrey J. Olson

Research output: Contribution to journalReview articlepeer-review

47 Scopus citations

Abstract

Question: Which imaging techniques most accurately differentiate true tumor progression from pseudo-progression or treatment related changes in patients with previously diagnosed glioblastoma? Target population: These recommendations apply to adults with previously diagnosed glioblastoma who are suspected of experiencing progression of the neoplastic process. Recommendations Level II: Magnetic resonance imaging with and without gadolinium enhancement is recommended as the imaging surveillance method to detect the progression of previously diagnosed glioblastoma. Level II: Magnetic resonance spectroscopy is recommended as a diagnostic method to differentiate true tumor progression from treatment-related imaging changes or pseudo-progression in patients with suspected progressive glioblastoma. Level III: The routine use of positron emission tomography to identify progression of glioblastoma is not recommended. Level III: Single-photon emission computed tomography imaging is recommended as a diagnostic method to differentiate true tumor progression from treatment-related imaging changes or pseudo-progression in patients with suspected progressive glioblastoma.

Original languageEnglish (US)
Pages (from-to)435-460
Number of pages26
JournalJournal of neuro-oncology
Volume118
Issue number3
DOIs
StatePublished - Jul 2014

Keywords

  • Glioblastoma
  • Imaging
  • Malignant glioma
  • Practice guideline
  • Progression
  • Pseudo-progression
  • Radiology
  • Recurrence
  • Systematic review

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Fingerprint

Dive into the research topics of 'The role of imaging in the management of progressive glioblastoma: A systematic review and evidence-based clinical practice guideline'. Together they form a unique fingerprint.

Cite this